Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 4
2012 1
2013 8
2014 4
2015 1
2016 3
2017 2
2018 5
2019 3
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Retraction.
Brand TM, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. Brand TM, et al. Sci Signal. 2021 Nov 9;14(708):eabn0168. doi: 10.1126/scisignal.abn0168. Epub 2021 Nov 9. Sci Signal. 2021. PMID: 34752142 Free PMC article. No abstract available.
Adaptive responses to antibody based therapy.
Rodems TS, Iida M, Brand TM, Pearson HE, Orbuch RA, Flanigan BG, Wheeler DL. Rodems TS, et al. Among authors: brand tm. Semin Cell Dev Biol. 2016 Feb;50:153-63. doi: 10.1016/j.semcdb.2016.01.001. Epub 2016 Jan 22. Semin Cell Dev Biol. 2016. PMID: 26808665 Review.
Nuclear EGFR as a molecular target in cancer.
Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Brand TM, et al. Radiother Oncol. 2013 Sep;108(3):370-7. doi: 10.1016/j.radonc.2013.06.010. Epub 2013 Jul 3. Radiother Oncol. 2013. PMID: 23830194 Free PMC article. Review.
AXL mediates resistance to cetuximab therapy.
Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. Brand TM, et al. Cancer Res. 2014 Sep 15;74(18):5152-64. doi: 10.1158/0008-5472.CAN-14-0294. Epub 2014 Aug 18. Cancer Res. 2014. PMID: 25136066 Free PMC article.
Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Brand TM, et al. Cancer Res. 2022 Sep 2;82(17):3187. doi: 10.1158/0008-5472.CAN-22-1308. Cancer Res. 2022. PMID: 36052496 No abstract available.
Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Brand TM, et al. Cancer Res. 2022 Sep 2;82(17):3188. doi: 10.1158/0008-5472.CAN-22-1307. Cancer Res. 2022. PMID: 36052495 No abstract available.
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR. Hedberg ML, et al. Among authors: brand tm. J Exp Med. 2019 Feb 4;216(2):419-427. doi: 10.1084/jem.20181936. Epub 2019 Jan 25. J Exp Med. 2019. PMID: 30683736 Free PMC article. Clinical Trial.
32 results